Status Complete
Process CG
Topic area
  • Central nervous system


Key events during the development of the guidance:

Date Update
06 September 2016 - 19 September 2016 Surveillance consultation
02 September 2016 Stakeholder list updated
13 June 2011 Development of the clinical guideline is under way and is being led by the National Collaborating Centre. The Guideline Development Group meets regularly to oversee and assist the identification, review and synthesis of the evidence, the incorporation of expert consensus opinion and the translation of the evidence into recommendations for practice and audit criteria. Two versions of the guideline are under preparation: a full guideline and a NICE short-form guideline. Please see timescales above for dates of consultation with stakeholders.
17 December 2010 The scope for spasticity in children in young people has been updated. When the scope was being developed, stakeholders requested that the guideline should make recommendations on the use of selective dorsal rhizotomy (SDR), a fairly new surgical intervention for treating spasticity in people with cerebral palsy. This was not possible at that time as there was already guidance from NICE’s interventional procedures (IP) programme on this intervention which highlighted concerns about the efficacy of SDR. The IP guidance on selective dorsal rhizotomy for spasticity in celebral palsy has now been updated stating that the evidence on efficacy is adequate and that this procedure may be used in the NHS provided that a hospital’s normal arrangements are in place for clinical governance and audit. This change in guidance recommendations allows this procedure to now be considered as part of the clinical guideline. The scope has been updated to reflect the inclusion of this procedure.
17 June 2010 The scope defines what aspects of care are covered by the guideline and to whom it applies. Comments that were made by stakeholders during the consultation on the scope can be seen in the scope consultation table.The Guideline Development Group (GDG) oversees the development process.

The NCCs may make a focussed call for evidence on specific clinical questions or subquestions, after it has done initial searches. It will be able to make a call at any point during development of the guideline, and stakeholders will usually be given 4weeks to respond. The NCC will approach all registered stakeholders for this evidence. The NCC may not issue any calls for evidence for a guideline if the Guideline Development Group (GDG) feels it is not necessary. In addition, the NCCs will accept relevant confidential data for consideration by the GDG.
18 August 2009 The remit was received from the Department of Health and the Welsh Assembly Government in August 2009 as part of the Institute’s 22nd wave work programme